---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-265830"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-06-10T20:09:58+00:00"
generated_at: "2026-06-10T20:11:55.185330+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM

## Summary
- 56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.
- All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.
- Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.
- No other significant proposals; no change in board composition or auditor.

## SEC filing metadata
- accession: 0001193125-26-265830
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-06-10T20:09:58+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/engn-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-265830
- JSON: https://secwatch.observer/filing/0001193125-26-265830.json
- Plain text: https://secwatch.observer/filing/0001193125-26-265830.txt

## Key facts
- Shareholder Votes
  enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 2 – Appointment and Remuneration of Auditor For Withhold Broker Non-Votes 56,180,287 16,015 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm
- Shareholder Votes
  enGene Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Philip Astley-Sparke 47,112,414 306,821 8,777,067 Ronald H.W. Cooper 47,329,848 89,387 8,777,067 Dr. William Grossman 47,408,163 11,072 8,777,067 Michael Heffernan 47,408,163 11,072 8,777,067
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.